IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Michel J.N. CORMIER, et al.

Group Art Unit: 1762

Serial Number: 10/045,842

Examiner: Erma C. Cameron

Filing Date: October 26, 2001

CONFIRMATION NO: 2394

Title: TRANSDERMAL DRUG DELIVERY
DEVICES HAVING COATED

MICROPROTRUSIONS

FILED ELECTRONICALLY ON: April 17, 2007

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

 A. \$\int 37 CFR \circ 1.97(b)\$. This Information Disclosure Statement should be considered because: 				
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under $\S1.53(d)$;	
			OR	
		(2)	It is being filed within 3 months of entry of the national stage as set forth in $\S1.491$ in an international application;	
			OR	
		(3)	It is being filed before the mailing of a first Office action on the merits;	
			OR	
		(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under $\S 1.114$.	
B. \(\simeg 37 CFR \)\(\frac{9}{1.97}(c)\). Although this Information Disclosure Statement is being filed after the p specified in 37 CFR \(\frac{9}{1.97}(b)\), above, it is filed before the mailing date of the earlier of (1) a office action under \(\frac{8}{1.113}\), (2) a notice of allowance under \(\frac{8}{1.311}\), or (3) an action that other closes prosecution on the merits, this Information Disclosure Statement should be considered ber it is accompanied by one of:				
		a states	ment as specified in §1.97(e) provided concurrently herewith;	
			OR	
	\boxtimes		f $\$180.00$ as set forth in $\$1.17(p)$ authorized below, enclosed, or included with the nt of other papers filed together with this statement.	
C.	date of the	earlier of	d). Although this Information Disclosure Statement is being filed after the mailing of (1) a final office action under $\S1.113$ or (2) a notice of allowance under $\S1.311$, fore payment of the issue fee and should be considered because it is accompanied	
		i. a st	atement as specified in §1.97(e);	
			AND	
			ee of $\$180.00$ as set forth in $\$1.17(p)$ is authorized below, enclosed, or included h the payment of other papers filed together with this Statement.	
D.	☐ 37 CFI	R §1.97((e). Statement.	
		A state	ement is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);	
			AND/OR	
		A state	ement is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);	
			AND/OR	
		inform the co	y of a dated communication from a foreign patent office clearly showing that the ation disclosure statement is being submitted within 3 months of the filing date on mmunication is provided in lieu of a statement under 37 C.F.R. § 1.97(e)(1) as ed for under MPEP 609.04(b) V.	
Е.	☐ Statement Under 37 C.F.R. §1.704(d). Each item of information contained in the informat disclosure statement were first cited in a communication from a foreign patent office in a counter application that was received by an individual designated in § 1.56(c) not more than thirty (30) deprior to the filing of this information disclosure statement. This statement is made pursuant to			

		ant(s) delay.
F.		R §1.98(a)(2). The content of the Information Disclosure Statement is as follows:
		Copies of each of the references listed on the attached Form $PTO/SB/08$ are enclosed herewith.
		OR
	\boxtimes	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.
		AND/OR
		Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR $\S1.98$ (a)(2).
		AND/OR
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR $\S1.98(a)(2)(iii)$.
G.	37 CF. references.	R §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or
		Pursuant to 37 CFR $\S1.98(a)(3)(i)$, a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.
		Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.
		OR
		A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:
		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.
Η.	37 CF	R §1.98(d). Copies of patents, publications and pending U.S. patent applications, or other n specified in 37 C.F.R. § 1.98(a) are not provided herewith because:
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.
		Application in which the information was submitted:
		Information Disclosure Statement(s) filed on:
		AND
		The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR $\S1.98$.

of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.33392-754.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: April 17

Samir Elamrani, Reg. No. 43,601

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 066956

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/045,842	
				Filing Date	October 26, 2001	
STATEMENT BY APPLICANT		First Named Inventor	Michel J. N. Cormier			
(Use as many sheets as necessary)			essary)	Art Unit	1762	
		Examiner Name	Erma C. Cameron			
Sheet	1	Of	1	Attorney Docket Number	33392-754.201	

U.S. PATENT DOCUMENTS						
Examiner Initials*	No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentce or Applicant of Cited Document	Pages, Columns, Lines, Wher Relevant Passages or Relevar Figures Appear	
	1.	US 2002/0087182	07/04/2002	Trautman et al.		
	2.	US 6,050,988	04/18/2000	Zuck		
	3.	US 6,083,196	07/04/2000	Trautman et al.		
	4.	US 6,230,051	05/08/2001	Cormier et al.		
	5.	US 6,322,808	11/27/2001	Trautman et al.		
	6.	US 6,855,131	02/15/2005	Trautman et al.		
	7.	US 6,918,901	07/19/2005	Theeuwes et al		
	8.	US 6,953,589	10/11/2005	Trautman et al.		
	9.	US 7,131,960	11/07/2006	Trautman et al.		
	10.	US 7,184,826	02/27/2007	Cormier et al.		

Examiner	Date
Signature	Considered

Signature | Considered | February | Considered | Considered | February | Considered |